FDA uses warning letter to check up on DMAA recall

By Hank Schultz contact

- Last updated on GMT

FDA uses warning letter to check up on DMAA recall
In an unusual move, in a warning letter to a dietary supplement company the Food and Drug Administration has sought information about a recall, in this case one involving DMAA products.

In a warning letter issued to Naturecom Inc.​ of Lake Forest, CA, FDA included a paragraph in the latter portion of the letter that read like this:

“Additionally, we have the following comment. We acknowledge that you have voluntarily recalled your products containing 1,3-dimethylamylamine, also known as DMAA or geranium extract. Please provide this office with the status of your activities of this on-going recall and any action plan you have to prevent this from reoccurring.”

Unusual facet of warning letter

Attorney Ivan Wasserman, a partner in the firm Amin Talati Upadhye, said this is a highly unusual occurrence, to include an inquiry of this sort in a warning letter that is otherwise focused on more or less standard observances of GMP shortcomings.

“It seems odd to include it in a warning letter,”​ Wasserman told NutraIngredients-USA. “I have never seen a ‘comment’ like this is a communication of this sort.”

Wasserman did note that the warning letter was issued by the Los Angeles district office.  District offices have the task of overseeing recalls in their areas.  In late November 2016,  Naturecom issued a voluntary recall​ for seven lots of what it called its “DMAA net weight 500g​” product because “there may be presence of DMAA,”​  though later in teh recall notice the company said the pouch products “contain 500g of DMAA.​”

GMP failures

The body of the warning letter pointed to what FDA said were various GMP failures on the part of thewhich firm, which mostly revolved around problems with batch records and master manufacturing records and also errors in labeling.  At several points in the letter, FDA cited teh company for being too vague in its response.  The following comment was typical of FDA’s opinion of the company’s response:

We have reviewed your December 18, 2016, response; however, we are unable to evaluate the adequacy of your corrective action. Your response states that you have established MMRs for each batch size of a dietary supplement that you manufacture. However, the MMRs provided in your response failed to include actual or representative labels associated with them.

The lesson to be learned, Wasserman said, is to be as specific as possible about what you plan to do and when you plan to do it.

The best way to avoid a warning letter is to fix as many things as possible during the course of the actual inspection,” ​Wasserman said. If there are 483s ​(observations of problems cited in the inspection report), you need to be very specific in your responses, not only about what you intend to do but the time frame within which you intend to do it.  FDA does not like generalities.

Related news

Related products

show more

Successful beverage delivery systems for every age

Successful beverage delivery systems for every age

Gelita AG | 08-Nov-2017 | Technical / White Paper

The importance of adequate fluid intake for a healthy and active life is well understood, and drinking a variety of beverages is part of many people’s...

Solve it with Solvay

Solve it with Solvay

Solvay Aroma Performance | 13-Oct-2017 | Product Presentation

There is growing consumer interest in high-protein products, yet the inherent off-flavors, regardless of protein type, mean manufacturers are faced with...

Natural, slow-release caffeine by Lipofoods

Natural, slow-release caffeine by Lipofoods

Lipofoods, a Lubrizol Company | 25-Sep-2017 | Data Sheet

Lipofoods presents NEWCAFF™ microcapsules, a natural, slow-release caffeine with a clean non-bitter taste, ideal for sports and nutrition products targeting...

Related suppliers

1 comment

Not the good kind of Unconventional Wisdom...

Posted by Brandon Griffin - Ingredient Identity,

Ivan...great summation sir! Our recommendation to companies going through such issues is if they do not have anyone with direct experience engaging the FDA regarding this specific matter, do not handle it without having that expertise on hand, starting from the very first response, period. The repercussions of trying to do it independently just continue to pile up, get worse and get way more expensive in >99% of the cases leading up to a Warning Letter getting issued and beyond. This is not to fear monger or drive business in any direction nor say that it is impossible for someone to address it themselves. Rather, this is just fact. All of those original observations were preventable in the first place, but clearly not as prioritized by their management as they should have been. A good Product Recall SOP would have helped!

Report abuse

Follow us

Products

View more

Webinars